The recent clinical successes of immunotherapy, as a result of a broader and more profound
understanding of cancer immunobiology, and the leverage of this knowledge to effectively …

Genetically engineered T cells are powerful new medicines, offering hope for curative
responses in patients with cancer. Chimaeric antigen receptors (CARs) are a class of …

INTRODUCTION TP53 (tumor protein P53), a tumor suppressor gene, is the most commonly
mutated cancer-driver gene. Nevertheless, drugs that target mutant p53, the protein product …

The cellular processes that govern tumor resistance to immunotherapy remain poorly
understood. To gain insight into these processes, here we perform a genome-scale CRISPR …

Chimeric antigen receptors (CAR) are recombinant receptors that provide both antigen-
binding and T-cell–activating functions. A multitude of CARs has been reported over the past …

T cells have the capacity to eradicate diseased cells, but tumours present considerable
challenges that render T cells ineffectual. Cancer cells often make themselves …

Rational design of chimeric antigen receptors (CARs) with optimized anticancer
performance mandates detailed knowledge of how CARs engage tumor antigens and how …

Twenty-five years after its inception, the genetic engineering of T cells is now a therapeutic
modality pursued at an increasing number of medical centers. This immunotherapeutic …

Background The genetic engineering of T cells through the introduction of a chimeric
antigen receptor (CAR) allows for generation of tumor‐targeted T cells. Once expressed by T …

T cell activation is a crucial checkpoint in adaptive immunity, and this activation depends on
the binding parameters that govern the interactions between T cell receptors (TCRs) and …